ArticleDrug design, development and therapy2026

Anlotinib as Third-Line or Later Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Real-World Efficacy and Safety Outcomes.

Yanwei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.